Senseonics Holdings, Inc. (NYSE:SENS) Receives $1.54 Average Target Price from Analysts

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $1.5375.

A number of brokerages have recently commented on SENS. TD Cowen began coverage on shares of Senseonics in a report on Tuesday, July 15th. They set a “buy” rating and a $1.25 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $1.40 price target (up previously from $1.10) on shares of Senseonics in a report on Tuesday, July 8th. Lake Street Capital upgraded shares of Senseonics to a “strong-buy” rating in a report on Thursday, July 17th. Finally, Barclays began coverage on shares of Senseonics in a report on Wednesday, August 27th. They set an “overweight” rating and a $1.50 price target on the stock.

Senseonics Price Performance

Shares of NYSE:SENS opened at $0.46 on Friday. The firm has a market cap of $375.81 million, a PE ratio of -3.55 and a beta of 0.93. The firm’s fifty day moving average is $0.48 and its 200-day moving average is $0.55. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics has a 52 week low of $0.25 and a 52 week high of $1.40.

Hedge Funds Weigh In On Senseonics

Hedge funds and other institutional investors have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in Senseonics in the first quarter valued at $31,000. IFP Advisors Inc lifted its holdings in Senseonics by 120.9% in the first quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock valued at $31,000 after buying an additional 26,000 shares during the period. Two Sigma Investments LP acquired a new position in Senseonics in the fourth quarter valued at $36,000. Smith Salley Wealth Management acquired a new position in Senseonics in the first quarter valued at $36,000. Finally, Elite Life Management LLC acquired a new position in Senseonics in the second quarter valued at $36,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.